“Proportion of Subjects Achieving a Molluscum Lesion Count of 0 or 1 at the Day 84 End of Study Visit in Phase 3 Clinical Trials with VP-102 CAMP-1 and CAMP-2”, J of Skin, vol. 5, no. 6, p. s92, Nov. 2021, doi: 10.25251/skin.5.supp.92.